Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axogen Inc (AXGN) vs Axon Enterprise Inc (AXON) Price & Performance

Axogen IncTrade
Axon Enterprise IncTrade

Price performance (Past 24H)

Key statistics

Axogen Inc vs Axon Enterprise Inc — how do they compare? Axogen Inc trades at $49.12 (market cap $2.61B), while Axon Enterprise Inc trades at $596.3 (market cap $51.69B). The key difference: Axon Enterprise Inc is far larger — about 19.8× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.

AXGNAXON
Market Cap
$2.61B$51.69B
Sector
TechnologyTechnology
52-Week High
$48.48$791.62
52-Week Low
$14.16$345.94
Enterprise Value
$2.52B$52.83B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axogen Inc

AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.

The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.

Axon Enterprise Inc

Axon Enterprise trades at $595.63, showing slight consolidation after recent strength with a bullish technical outlook. The company delivered strong Q2 2026 results with 35% revenue growth and raised full-year guidance, though valuation metrics remain elevated with a P/E of 265. Analyst sentiment is overwhelmingly positive with 81% buy ratings and a $685 consensus target.

Axon's razor-and-blade model drives hardware adoption and high-margin software growth, supported by AI capabilities and $15.1B in future contracted bookings. Key risks include valuation concerns, gross margin pressure from service mix, and execution challenges in scaling new products. The stock offers growth exposure but requires monitoring of margin trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Axogen Inc

Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.

Read more on AXGN

About Axon Enterprise Inc

Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.

Read more on AXON